Your browser doesn't support javascript.
loading
Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS.
Loke, Justin; McCarthy, Nicholas; Jackson, Aimee; Siddique, Shamyla; Hodgkinson, Andrea; Mason, John; Crawley, Charles; Gilleece, Maria; Peniket, Andrew; Protheroe, Rachel; Salim, Rahuman; Tholouli, Eleni; Wilson, Keith; Andrew, Georgia; Dillon, Richard; Khan, Naeem; Potter, Victoria; Krishnamurthy, Pramila; Craddock, Charles; Freeman, Sylvie.
Afiliación
  • Loke J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
  • McCarthy N; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Jackson A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Siddique S; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Hodgkinson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Mason J; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Crawley C; Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom.
  • Gilleece M; Addenbrookes Hospital, Cambridge, United Kingdom.
  • Peniket A; St James's Hospital, Leeds, United Kingdom.
  • Protheroe R; Churchill Hospital, Oxford, United Kingdom.
  • Salim R; Bristol Haematology and Oncology Centre, Bristol, United Kingdom.
  • Tholouli E; Royal Liverpool University Hospital, Liverpool, United Kingdom.
  • Wilson K; Manchester Royal Infirmary, Manchester, United Kingdom.
  • Andrew G; University Hospital of Wales, Cardiff, UK.
  • Dillon R; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Khan N; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
  • Potter V; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
  • Krishnamurthy P; Kings College Hospital, London, United Kingdom.
  • Craddock C; Kings College Hospital, London, United Kingdom.
  • Freeman S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Blood Adv ; 7(14): 3666-3676, 2023 07 25.
Article en En | MEDLINE | ID: mdl-37058448
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Mielodisplásicos / Leucemia Mieloide Aguda Tipo de estudio: Clinical_trials / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Blood Adv Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Estados Unidos